Juvenile Arthritis News

Children with chronic pain or rheumatic disease who experience adverse childhood events may be at a greater risk for worse symptoms and “functional disability,” according to data published in Pediatric Rheumatology.

Children with spondyloarthritis and polyarticular arthritis demonstrate greater internalized disturbances and worse psychological functioning in school and social arenas, according to data.

The American College of Rheumatology and the American Association of Hip and Knee Surgeons have released updated recommendations for the perioperative management of antirheumatic medication in patients undergoing hip and knee arthroplasty.

The American College of Rheumatology has released two updated guideline papers for the treatment and management of juvenile idiopathic arthritis, according to a press release.

Growth impairment was reported in 23.6% of children with systemic lupus erythematosus, with corticosteroid duration and exposure prior to late puberty identified as key risk factors, according to data published in Pediatric Rheumatology.

Exposure to TNF inhibitors nearly triples the risk for psoriasis among children with juvenile idiopathic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Overall satisfaction with telehealth visits was high for pediatric rheumatology patients and their caregivers during the COVID-19 pandemic, though there may be areas for improvement, according to data published in Pediatric Rheumatology.

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

Low disease activity and remission definitions used for adult systemic lupus erythematosus are achievable among children and can significantly reduce the risk for severe flare, according to data published in Rheumatology.

In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable biosimilar to AbbVie’s blockbuster drug, Humira — but, as rivals scramble for second place, will the designation be worth the price?